Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
ASCO 2022: Breast cancer highlights
Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
ASCO 2022: Breast cancer highlights ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )
6 Jun 2022
CheckMate 9ER: aRCC patients on nivolumab plus cabozantinib achieved deeper resp...
Dr Cristina Suarez - Vall d’Hebron University Hospital, Catalonia, Spain
CheckMate 9ER: aRCC patients on nivolumab plus cabozantinib achieved deeper responses vs sunitinib ( Dr Cristina Suarez - Vall d’Hebron University Hospital, Catalonia, Spain )
6 Jun 2022
FOLFOXIRI plus panitumumab vs mFOLFOX6/PAN for unresectable RAS and BRAF wild-ty...
Dr Chiara Cremolini - University of Pisa, Pisa, Italy
FOLFOXIRI plus panitumumab vs mFOLFOX6/PAN for unresectable RAS and BRAF wild-type mCC ( Dr Chiara Cremolini - University of Pisa, Pisa, Italy )
6 Jun 2022
Adjuvant endocrine therapy used to treat ER+ HER2- breast cancer
Dr Etienne Brain - Institut Curie, Paris, France
Adjuvant endocrine therapy used to treat ER+ HER2- breast cancer ( Dr Etienne Brain - Institut Curie, Paris, France )
6 Jun 2022
COSMIC-021: Cabozantinib plus atezolizumab gives encouraging clinical activity i...
Dr Sumanta K. Pal - City of Hope Comprehensive Cancer Center, Duarte, USA
COSMIC-021: Cabozantinib plus atezolizumab gives encouraging clinical activity in inoperable locally advanced/metastatic urothelial carcinoma ( Dr Sumanta K. Pal - City of Hope Comprehensive Cancer Center, Duarte, USA )
5 Jun 2022
Safety follow-up of the randomized, phase 3 study DESTINY-Breast03
Dr Erika Hamilton - Sarah Cannon Research Institute, Tennessee, USA
Safety follow-up of the randomized, phase 3 study DESTINY-Breast03 ( Dr Erika Hamilton - Sarah Cannon Research Institute, Tennessee, USA )
5 Jun 2022
Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDMM: Phase 3 D...
Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA
Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDMM: Phase 3 DETERMINATION trial ( Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA )
5 Jun 2022
Single-agent PD-1 blockade as curative-intent treatment in mismatch repair-defic...
Dr Andrea Cercek - Memorial Sloan Kettering Cancer Centre, Manhattan, New York
Single-agent PD-1 blockade as curative-intent treatment in mismatch repair-deficient locally advanced rectal cancer ( Dr Andrea Cercek - Memorial Sloan Kettering Cancer Centre, Manhattan, New York )
5 Jun 2022
Latest in testing and diagnostics in exon 20 NSCLC
Dr Antonio Passaro and Prof Paul Hofman
Latest in testing and diagnostics in exon 20 NSCLC ( Dr Antonio Passaro and Prof Paul Hofman )
4 Jun 2022
Ibrutinib improves PFS by 50% for older patients with newly diagnosed mantle cel...
Dr Michael Wang - MD Anderson Cancer Center, Houston, USA
Ibrutinib improves PFS by 50% for older patients with newly diagnosed mantle cell lymphoma ( Dr Michael Wang - MD Anderson Cancer Center, Houston, USA )
4 Jun 2022
Circulating tumour DNA analysis can help identify the need for adjuvant therapy ...
Dr Jeanne Tie - The Peter MacCallum Cancer Centre, Melbourne, Australia
Circulating tumour DNA analysis can help identify the need for adjuvant therapy in stage II colon cancer ( Dr Jeanne Tie - The Peter MacCallum Cancer Centre, Melbourne, Australia )
4 Jun 2022
Sacituzumab goviteca provides clinically meaningful PFS benefit for hormone rece...
Dr Hope Rugo - University of California San Francisco, San Francisco, USA
Sacituzumab goviteca provides clinically meaningful PFS benefit for hormone receptor HR+/HER2‐ advanced breast cancer patients ( Dr Hope Rugo - University of California San Francisco, San Francisco, USA )
4 Jun 2022